Literature DB >> 3937015

[Morbidity in Chagas' disease. IV. Longitudinal study of 10 years in Pains and Iguatama, Minas Gerais, Brazil].

J R Coura, L L de Abreu, J B Pereira, H P Willcox.   

Abstract

An evolutive study of the "case-control" type was carried out in an endemic area of Chagas' disease in Minas Gerais State, Brazil, using two cross-section evaluations with an interval of ten years between them (1974-1984). Patients were paired for sex and age. In the first cross-section study 264 pairs one with a positive serology and the other with a negative serology for T. cruzi antibodies were included. In the second evaluation, ten years later, 235 patients among those with previous positive serology and 216 with negative serology were located, but only 110 pairs could be recomposed and reexamined (clinical examination, ECG and Rx of the heart and esophagus). The incidence of chagasic cardiopathy in the cases with positive serology but previously assymptomatic was 38.3% during the ten year period. On the other hand there was a deterioration in 24% of the patients with chagasic cardiopathy since the first examination. Considering all clinical forms of the disease in 34.5% of the patients the clinical situation deteriorated, in 57.3% there was no change and in 8.2% the situation improved. The general mortality in the period was 23% in the chagasic group and 10.6% in the control group, but the lethality by cardiopathy was 17% in chagasic group and only 23.3% in the control group. The mortality was twice as high in males than in females, mainly in the age group from 30 to 59 years.

Entities:  

Mesh:

Year:  1985        PMID: 3937015     DOI: 10.1590/s0074-02761985000100011

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  11 in total

1.  Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up of Trypanosoma cruzi-Seropositive Individuals.

Authors:  Maria Carmo P Nunes; Lewis F Buss; Antonio Luiz P Ribeiro; Ester Cerdeira Sabino; Jose Luiz P Silva; Larissa Natany A Martins; Claudia Di Lorenzo Oliveira; Clareci Silva Cardoso; Bruno Oliveira de Figueiredo Brito; Ariela Mota Ferreira; Lea Campos Oliveira; Ana Luiza Bierrenbach; Fabio Fernandes; Michael P Busch; Viviane Tiemi Hotta; Luiz Mario Baptista Martinelli; Maria Carolina F Almeida Soeiro; Adriana Brentegani; Vera M C Salemi; Marcia M Menezes
Journal:  Circulation       Date:  2021-09-27       Impact factor: 29.690

Review 2.  Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy.

Authors:  Claudio A Muratore; Adrian Baranchuk
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

3.  In situ expression of regulatory cytokines by heart inflammatory cells in Chagas' disease patients with heart failure.

Authors:  Denise Bertulucci Rocha Rodrigues; Marlene Antonia dos Reis; Audrey Romano; Sanívia Aparecida de Lima Pereira; Vicente de Paula Antunes Teixeira; Sebastião Tostes; Virmondes Rodrigues
Journal:  Clin Dev Immunol       Date:  2012-07-03

Review 4.  Chagas disease research and development: Is there light at the end of the tunnel?

Authors:  Eric Chatelain
Journal:  Comput Struct Biotechnol J       Date:  2016-12-14       Impact factor: 7.271

5.  Progression Rate from the Indeterminate Form to the Cardiac Form in Patients with Chronic Chagas Disease: Twenty-Two-Year Follow-Up in a Brazilian Urban Cohort.

Authors:  Alejandro Marcel Hasslocher-Moreno; Sergio Salles Xavier; Roberto Magalhães Saraiva; Luiz Henrique Conde Sangenis; Marcelo Teixeira de Holanda; Henrique Horta Veloso; Andrea Rodrigues da Costa; Fernanda de Souza Nogueira Sardinha Mendes; Pedro Emmanuel Alvarenga Americano do Brasil; Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Andrea Silvestre de Sousa
Journal:  Trop Med Infect Dis       Date:  2020-05-12

6.  Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease.

Authors:  Ana Yecê das Neves Pinto; Vera da Costa Valente; José Rodrigues Coura; Sebastião Aldo da Silva Valente; Angela Cristina Veríssimo Junqueira; Laura Cristina Santos; Alberto Gomes Ferreira; Roberto Cavalleiro de Macedo
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

7.  Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.

Authors:  Clara Crespillo-Andújar; Emmanuele Venanzi-Rullo; Rogelio López-Vélez; Begoña Monge-Maillo; Francesca Norman; Ana López-Polín; José A Pérez-Molina
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.228

8.  Myenteric plexus is differentially affected by infection with distinct Trypanosoma cruzi strains in Beagle dogs.

Authors:  Nívia Carolina Nogueira-Paiva; Kátia da Silva Fonseca; Paula Melo de Abreu Vieira; Lívia Figueiredo Diniz; Ivo Santana Caldas; Sandra Aparecida Lima de Moura; Vanja Maria Veloso; Paulo Marcos da Matta Guedes; Washington Luiz Tafuri; Maria Terezinha Bahia; Cláudia Martins Carneiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11-04       Impact factor: 2.743

Review 9.  Increased mortality attributed to Chagas disease: a systematic review and meta-analysis.

Authors:  Zulma M Cucunubá; Omolade Okuwoga; María-Gloria Basáñez; Pierre Nouvellet
Journal:  Parasit Vectors       Date:  2016-01-27       Impact factor: 3.876

10.  Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis.

Authors:  Sindhu Chadalawada; Stefan Sillau; Solana Archuleta; William Mundo; Mehdi Bandali; Gabriel Parra-Henao; Alfonso J Rodriguez-Morales; Wilmer E Villamil-Gomez; José Antonio Suárez; Leland Shapiro; Peter J Hotez; Laila Woc-Colburn; Kristen DeSanto; Anis Rassi; Carlos Franco-Paredes; Andrés F Henao-Martínez
Journal:  JAMA Netw Open       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.